Eli Lilly's marketer, Allogene's CAR-T therapy sale and Merck's acquisition of Terns were discussed on "The Readout LOUD" podcast this week. Merck is buying Terns Pharma for $6.7 billion, valuing Terns shares at $53 apiece, a 6 percent premium to its previous closing price. Terns shares have risen sixfold in the past six months on the potential of TERN-701's leukemia drug. Eli Lilly forecasts 2026 revenue in the range of $80 billion to $83 billion, which is an average of $81.5 billion and exceeds the analyst consensus by 3.8 percent. He expects earnings per share to be between $33.50 and $35.00, an average of $34.25, which is 2.9 percent above expectations. The FDA will rule on Orforglipron, an oral GLP-1 anti-obesity pill, on April 10 after four positive phase 3 studies.[9][6][10]